title: Why an abbreviated FDA pathway for biosimilars is overhyped.
authors: Henry I
authors: HI
authors: Miller
mesh_terms: D001688:Biological Products / Q000592:standards; D001702:Biopharmaceutics / Q000191:economics / Q000331:legislation & jurisprudence*; D001709:Biotechnology / Q000331:legislation & jurisprudence / Q000379:methods; D016568:Drugs, Generic / Q000191:economics / Q000592:standards*; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
chemical_list: D001688:Biological Products; D016568:Drugs, Generic